What is QurAlis?
QurAlis is at the forefront of developing precision medicines for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). Leveraging proprietary platforms and unique biomarkers, the company designs and advances drugs that directly target disease-causing genetic alterations. Founded by a distinguished team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is building a robust pipeline of antisense oligonucleotide and small molecule programs. These initiatives are specifically designed to address sub-forms of ALS that represent the majority of patient cases, aiming for a significant impact on patient outcomes.
How much funding has QurAlis raised?
QurAlis has raised a total of $150M across 3 funding rounds:
Series A
$42M
Series B
$88M
Debt
$20M
Series A (2020): $42M with participation from Mitsui Global Investment, Dementia Discovery Fund, INKEF Capital, LS Polaris Innovation Fund, Droia Ventures, Mission BioCapital, Sanford Biosciences, MP Healthcare Venture Management, Amgen Business Development, and Dolby Family Ventures
Series B (2023): $88M led by Sanofi Ventures
Debt (2025): $20M, investors not publicly disclosed
Key Investors in QurAlis
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, specializing in early-stage biotech and digital health companies with innovative technologies of strategic interest to Sanofi, particularly in areas like oncology, immunology, and rare diseases.
Mitsui Global Investment
Mitsui Global Investment, Inc. provides financial and strategic guidance to innovative entrepreneurs, aiming to help them reach the global stage. With extensive experience and a focus on reinventing industries, they partner with exceptional teams to improve human welfare.
Dementia Discovery Fund
The Dementia Discovery Fund is a venture capital fund dedicated to investing in companies developing treatments for dementia and other neurodegenerative diseases, aiming to accelerate the discovery and development of novel therapies.
What's next for QurAlis?
With the recent major strategic investment, QurAlis is poised for accelerated growth and pipeline advancement. The substantial capital injection, part of its $150M in total financing, signals strong investor confidence in the company's approach to neurodegenerative diseases. This funding will likely be instrumental in advancing QurAlis' preclinical and clinical programs, expanding its research and development capabilities, and potentially forging strategic partnerships to bring its innovative therapies to patients suffering from ALS and other related conditions. The company's focus on genetically validated targets and precision medicine positions it as a key player in the evolving landscape of neurological therapeutics.
See full QurAlis company page
